PepGen: A High-Stakes, Single-Asset Biotech with Blockbuster Potential in Myotonic Dystrophy
Overview
PepGen is a clinical-stage biotech company now fully concentrated on developing PGN-EDODM1 using its proprietary EDO platform to treat Myotonic Dystrophy Type 1 (DM1). The company's strategic refocus followed disappointing DMD trial results and has streamlined operations and cash burn. Investment prospects now rest on PGN-EDODM1's continued success, supported by outstanding Phase 1 splicing correction results and sufficient funding after a $115M capital raise. While this strategic narrowing boosts focus, it also increases binary risk, with the company's fate tied to a single clinical program and its efficacy, competitive standing, and regulatory trajectory. The report’s scenario-based, risk-adjusted valuation estimates the stock's probability-weighted 5-year price target at $28.13, with a potential high of $55 and a low of $1.50 depending on clinical outcomes.